

Evolocumab

Chemical Properties

CAS No.:	1256937-27-5
Formula:	N/A
Molecular Weight:	N/A
Appearance:	N/A
Storage:	store at -20°C

Biological Description

Description	Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 Proprotein Convertase Subtilisin Kexin Type 9).
Targets(IC ₅₀)	PCSK9: None
In vivo	In mice, a single intravenous injection of evolocumab 10 mg/kg reduced total cholesterol by 20, 26, and 28% at 24, 72, and 144 h after injection, respectively. The magnitude and duration of the effects of evolocumab were dose related: total cholesterol at 3 days after an injection of evolocumab 3, 6, or 10 mg/kg was reduced from baseline by 26, 28, and 36%, respectively. By day 12, total cholesterol levels in all treatment groups were similar to those in control animals.

Solubility Information

Solubility	< 1 mg/ml refers to the product slightly soluble or insoluble
------------	---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Sreeneeranj Kasichayanula, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor. Clin Pharmacokinet. 2018; 57(7): 769–779.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481